99% Rapamycin API Of GMP Manufacturer

Q1: What is Rapamycin API used for?

A1: Rapamycin API is used as an active pharmaceutical ingredient in immunosuppressive therapy for organ transplant rejection (Rapamune®), for treating lymphangioleiomyomatosis (LAM), in drug‑eluting stents, and increasingly in off‑label compounding for longevity, immunomodulation, and age‑related conditions. Compounding pharmacies prepare low‑dose capsules and oral suspensions under a physician’s prescription.

Q2: What is the difference between Rapamycin, Sirolimus, and Everolimus?

A2: Rapamycin and Sirolimus are the same compound. Everolimus is a semi‑synthetic derivative (40‑O‑(2‑hydroxyethyl)‑rapamycin) with slightly different pharmacokinetics (shorter half‑life and improved oral bioavailability). Both are mTOR inhibitors, but our focus is on Rapamycin/Sirolimus API.

Q3: Are you a registered Rapamycin API supplier?

A3: Yes. Our manufacturing site is GMP‑certified for immunosuppressant APIs. We have supplied Rapamycin API to generic drug manufacturers, stent coating companies, and compounding pharmacies globally. A DMF Type II (US, Canada, EU, China) is available for cross‑reference.

Q4: What is your minimum order quantity (MOQ) for compounding pharmacies?

A4: For licensed compounding pharmacies, our MOQ is 250 mg for non‑sterile compounding grade. We also offer 100 mg trial sizes. For sterile research-grade, the MOQ is 100 mg. We encourage small orders for pilot batches and patient‑specific preparations.

Q5: How do you protect Rapamycin from degradation during shipping?

A5: All shipments are packaged with cold packs (2–8 °C), nitrogen‑flushed aluminum bags, desiccant, and light‑impermeable outer containers. For international shipments, we use validated cold chain couriers with temperature data loggers upon request.

Q6: Do you provide a Certificate of Analysis (COA) with each batch?

A6: Yes. Each batch includes a COA showing assay, impurity profile (including rapamycin-related compound A), water content, residual solvents, particle size (if applicable), and (for sterile grade) endotoxin and sterility results. Stability data and MSDS are also provided.

Q7: Can you supply micronized Rapamycin API for low‑dose capsules?

A7: Yes. Our micronized grade (D90 ≤ 20 µm) is specifically designed for low‑dose capsules (1–6 mg) where content uniformity is critical. Micronization also improves dissolution in oral suspensions.

Q8: Is Rapamycin API stable in common compounding vehicles?

A8: Rapamycin is unstable in aqueous solutions at neutral or alkaline pH (rapid ring opening). For oral suspensions, oil‑based vehicles (MCT oil, olive oil) with antioxidants (0.01% BHT) are recommended. For capsules, dry powder is filled into size 4 or 5 capsules with silica gel desiccant inside the container. We provide formulation guidance and accelerated stability data for specific vehicles upon request.

Q9: Do you offer sterile Rapamycin API for injectable research?

A9: We offer sterile filtered Rapamycin API for research purposes only (not for human injection). This grade is intended for in‑vitro studies, animal research, or pre‑clinical formulation development. Please contact us with your research protocol to ensure appropriate grade selection.

Q10: What documentation do you provide for regulatory filing?

A10: We provide a complete DMF, including synthetic route, impurity profiling (with forced degradation and photostability studies), method validation (HPLC, GC‑HS, LC‑MS/MS), stability data (accelerated and long‑term at 2–8 °C and 25 °C), elemental impurities (ICH Q3D), and residual solvent analysis.

Q11: What is the recommended beyond‑use date (BUD) for compounded low‑dose Rapamycin capsules?

A11: For dry powder filled into gelatin capsules with a desiccant canister inside a light‑protected HDPE bottle, stored refrigerated (2–8 °C), we recommend a BUD of 90 days. For oil‑based oral suspensions (MCT oil with 0.01% BHT): refrigerated for 60 days. Always include a desiccant and seal the container tightly. We provide BUD verification studies upon request.

Q12: What is the lead time for delivery to North America or Europe?

A12: Standard grade: 10 days after order confirmation. Micronized grade: 14 days. Sterile research grade: 21 days. Cold-chain express courier service (2–5 days) is required and included in our shipping quotes.

Q13: Can you provide R&D samples for formulation feasibility studies?

A13: Yes. We offer free R&D samples (up to 100 mg) to qualified pharmaceutical R&D departments and licensed compounding pharmacies. The customer pays only for cold chain shipping. A material transfer agreement (MTA) is required. For larger feasibility batches (250 mg – 1g), we charge a nominal fee, credited against the first commercial order.

Q14: How do you compare with other Rapamycin API suppliers (China, India, Europe)?

A14: We combine GMP manufacturing with transparent, third‑party‑tested quality data, strictly controlled cold chain logistics, shorter lead times to Western markets (via regional refrigerated warehouses), and dedicated English‑speaking technical support. Unlike many suppliers, we actively support small‑volume compounding pharmacy orders (as low as 100 g) and provide formulation assistance for low‑dose longevity protocols.

Q15: Is Rapamycin API stable at room temperature for compounding?

A15: Short‑term exposure (less than 24 hours) to room temperature (15–30 °C) during compounding is acceptable, but the bulk API should be returned to refrigeration immediately after use. Prolonged storage at room temperature will accelerate degradation (especially open‑ring impurity). Always store compounded capsules or suspensions in a refrigerator (2–8 °C) and dispense with a “refrigerate” label.

Q16: Can Rapamycin be used in transdermal preparations?

A16: Rapamycin has a moderate molecular weight (914 Da) and poor skin penetration in its native form. Some compounding pharmacies use penetration enhancers (DMSO, propylene glycol, or PLO gel) to improve delivery. However, transdermal bioavailability is highly variable. We recommend oral or sublingual routes for systemic effects unless specifically prescribed for localized dermatologic conditions (e.g., facial angiofibromas). We can provide compatibility data for PLO bases upon request.

Q17: What is the standard dosing for longevity or anti‑aging protocols?

A17: We do not provide medical advice. Typical off‑label protocols described in the literature range from 1–6 mg taken once weekly or every 5 days, often with a washout period. Compounding pharmacies should follow the prescribing physician’s exact formulation instructions.